Small molecule biotechnology company Iambic Therapeutics (IAM.US) sets IPO price at $15-17 per share, plans to raise $150 millions
智通财经2026/10/09 07:06According to Jinse Finance, it has been reported that Iambic Therapeutics (IAM.US), a biotechnology company developing small-molecule anti-cancer therapies based on its self-developed artificial intelligence (AI) platform and currently in Phase I clinical trials, announced its IPO terms on Thursday. The San Diego, California-based company plans to raise $150 million by offering 9.4 million shares at a price range of $15 to $17 per share. Some investors have already expressed their intention to purchase $60 million worth of shares in this offering, accounting for 40% of the deal. At the midpoint of the proposed price range, Iambic Therapeutics would have a fully diluted market value of $809 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Fidelity, Arch support, RNAi emerging player City Therapeutics (CTY.US) aims for US IPO, plans to raise up to 185 millions dollars
According to Jinse Finance, early-stage RNAi drug developer City Therapeutics Inc. (CTY.US) is seeking to raise up to 184.7 millions USD in its U.S. initial public offering (IPO). According to documents filed with the U.S. Securities and Exchange Commission on Friday, the company, whose investors include Arch Venture Partners and Fidelity Management & Research, plans to issue 9.72 million shares at a price range of $17 to $19 per share.
The strongest growth outlook in over two years is in sight! The US stock market's medical device sector still needs to endure another sluggish earnings season.
Zhihu Finance APP noted that medical device companies are expected to go through another sluggish earnings season before entering 2027 with the strongest growth outlook in more than two years—following a challenging period for the industry marked by policy uncertainty, cyberattacks, and product recalls.
Pakistan National Oil Company signs oil supply agreement with Oman OQ
Pakistan's national oil company has signed an oil supply agreement with Oman OQ.
German businesses warn that French debt risks may surpass the Greek crisis
(1) Commerzbank warns that France's debt issues may pose an even greater systemic risk to the eurozone than the Greek sovereign debt crisis. (2) The institution points out that public debt in the eurozone currently averages about 90% of economic output, up from around 80% in 2009. (3) Meanwhile, the willingness of various parties to advance fiscal reforms has weakened. (4) However, a more robust banking system, French institutions, and the intervention tools of the European Central Bank have reduced the likelihood of risk contagion. (5) Commerzbank does not expect a new sovereign debt crisis to occur but warns that related risks are on the rise. (6) On the market front, France's fiscal trajectory and the sustainability of eurozone debt remain potential variables in the pricing of long-term interest rates. (7) Ongoing attention should be paid to the progress of French fiscal reforms and the application of European Central Bank policy tools.
Crypto prices
More
